<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="4" ids="48705">Agonists</z:chebi> of the <z:chebi fb="3" ids="16865">GABA</z:chebi>-A receptor are neuroprotective after experimental <z:hpo ids='HP_0001297'>stroke</z:hpo>, but studies of <z:chebi fb="3" ids="16865">GABA</z:chebi>-B <z:chebi fb="4" ids="48705">agonists</z:chebi> have contradicted each other </plain></SENT>
<SENT sid="1" pm="."><plain>To further investigate whether <z:chebi fb="3" ids="16865">GABA</z:chebi>-B <z:chebi fb="4" ids="48705">agonists</z:chebi> may be neuroprotective, we devised a quantal bioassay using the intraluminal occlusion method of inducing reversible <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects underwent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for varying amounts of time, ranging from 5 to 90 min </plain></SENT>
<SENT sid="3" pm="."><plain>Behavioral outcome was measured 48 h later with a quantal observational scale: score of abnormal given for any one of asymmetric forepaw flexion on tail lift, asymmetric grip, <z:mp ids='MP_0001394'>circling</z:mp>, reduced exploration, <z:hpo ids='HP_0001250'>seizures</z:hpo>, or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>To the grouped response data the logistic equation was used to find the ED50, the duration of occlusion that caused one-half of the subjects to be abnormal </plain></SENT>
<SENT sid="5" pm="."><plain>To find the potency ratio for each drug, we divided the ED50 for treatment by that for vehicle </plain></SENT>
<SENT sid="6" pm="."><plain>We administered <z:chebi fb="0" ids="2972">baclofen</z:chebi>, a <z:chebi fb="3" ids="16865">GABA</z:chebi>-B <z:chebi fb="4" ids="48705">agonist</z:chebi>, intraperitoneally 5 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> ofischemia </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="2972">Baclofen</z:chebi> (20 mg/kg) was neuroprotective (potency ratio of 3.0, P &lt; 0.05), but a lower dose (10 mg/kg) was not </plain></SENT>
<SENT sid="8" pm="."><plain>However, both doses of <z:chebi fb="0" ids="2972">baclofen</z:chebi> caused significantly more <z:hpo ids='HP_0001342'>intracerebral hemorrhages</z:hpo> than control </plain></SENT>
<SENT sid="9" pm="."><plain>In awake animals, both <z:chebi fb="0" ids="2972">baclofen</z:chebi> doses caused significant increases in mean arterial pressure, but no changes in other cardiorespiratory variables </plain></SENT>
<SENT sid="10" pm="."><plain>The <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> MK-801, the <z:chebi fb="3" ids="16865">GABA</z:chebi>-A <z:chebi fb="4" ids="48705">agonist</z:chebi> muscimol, and <z:hpo ids='HP_0002045'>hypothermia</z:hpo> were <z:hpo ids='HP_0000001'>all</z:hpo> protective using the bioassay (potency ratios ranging from 1.5 to 3.0) </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that although <z:chebi fb="0" ids="2972">baclofen</z:chebi> (20 mg/kg) may be neuroprotective, its utility is complicated by postischemic <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0001342'>cerebral hemorrhages</z:hpo> </plain></SENT>
</text></document>